Navamedic launches new product in Nordic markets
Navamedic ASA (OSE: NAVA) today announced that the Company is launching a new product in the Nordic markets. Expected annual sales of the product are more than NOK 3 million.
Navamedic is taking over Nordic distribution and sales of the product Florinef, which helps the adrenal glands retain sodium and act as a replacement for cortisone when the body does not produce enough. The product is an original pharmaceutical supplied by Navamedic's main supplier Aspen of South Africa.
For further information, please contact interim CEO Håkan Josephsson, telephone +46 706 742 533 or CFO Bjørn Lindholt, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 120 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).